Meeting Highlights From The Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 September 2015

The Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of nasal and mouth sprays containing the antibiotic fusafungine, used to treat infections of the upper airways. The PRAC aims to review the available data on the benefits and risks of these medicines and issue an opinion on their marketing authorisations across the European Union.

Help employers find you! Check out all the jobs and post your resume.

Back to news